GET DAILY SIGNALSNeumora Therapeutics (NMRA) Q3 2026 Earnings: Cash Runway and Pipeline Updates Take Center Stage
Key Takeaways
- Neumora Therapeutics (NMRA), a clinical-stage neuroscience biopharmaceutical company, is expected to report its third quarter 2026 results in early-to-mid November 2026, with consensus estimates pointing to a net loss of roughly $0.19 to $0.20 per share.
- As a pre-revenue company, Neumora reports no product sales; the focus is on operating expenses, net loss, cash position, and updated cash runway guidance.
- The quarter follows the June 2026 discontinuation of lead candidate navacaprant after the Phase 3 KOASTAL-2 and -3 studies missed their primary endpoints, prompting a roughly 35% workforce reduction.
- Investors will watch for updates on the remaining pipeline — NMRA-511, NMRA-898, and NMRA-215 — and confirmation that cash remains sufficient to fund operations into the third quarter of 2027.
- For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for additional insight.
- Discover Trending AI Robots to see how AI-driven trading strategies are approaching stocks like NMRA.
Why This Earnings Report Matters
Neumora's third quarter 2026 report lands at a pivotal moment. The company's lead asset, navacaprant, was discontinued in June 2026 after the KOASTAL-2 and -3 Phase 3 studies in major depressive disorder failed to meet their primary endpoints. That outcome triggered a roughly 35% reduction in headcount and a sharp repricing of the stock, which now trades near its 52-week low. With no approved products and no revenue, Neumora's quarterly earnings serve primarily as a checkpoint on spending discipline, cash runway, and the credibility of its earlier-stage pipeline. For investors, this report is less about a single number and more about whether management can preserve capital while advancing the programs that now define the company's future. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Neumora to report a net loss of approximately $0.19 to $0.20 per share for the third quarter of 2026, compared with a loss of $0.35 per share in the same period a year earlier. Revenue is expected to be zero, reflecting the company's pre-commercial status. The most recent quarter provides a benchmark: on August 14, 2026, Neumora reported a second quarter 2026 net loss of $43.1 million, or $0.23 per share, beating consensus estimates of about $0.24, with research and development (R&D) expenses falling roughly 24% year over year to $29.3 million. As of June 30, 2026, the company held $116.8 million in cash and cash equivalents, with guidance that this would fund operations into the third quarter of 2027. Investors will be watching whether that runway guidance is maintained or revised. From what I see, comparing these figures against peers can add useful context.
Market Reaction and Investor Sentiment
Sentiment heading into this report remains cautious. Since the navacaprant setback, NMRA shares have fallen sharply and now trade below $0.50, well under their one-year high of $3.65, with analyst ratings mixed and price targets pulled lower. The stock has historically moved on pipeline news more than on the headline earnings number. Key risks include any narrowing of cash runway guidance, higher-than-expected spending, or delays to upcoming clinical milestones. Because Neumora is pre-revenue, the earnings reaction will likely hinge on management's commentary about cost controls and the timing of data readouts for NMRA-511 and NMRA-898, both expected in the second half of 2026.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should focus on the company's remaining pipeline rather than traditional earnings metrics. The most important near-term catalyst is NMRA-511, a vasopressin 1a receptor antagonist being developed for agitation in Alzheimer's disease. Data from a multiple ascending dose (MAD) expansion cohort is expected in the fourth quarter of 2026, with a Phase 2 study anticipated to begin by the end of the year.
A second catalyst is NMRA-898, an M4 positive allosteric modulator being studied in schizophrenia. Phase 1 data are expected in the second half of 2026, and results will help determine whether the program advances. Finally, NMRA-215, an NLRP3 inhibitor targeting obesity, is expected to submit an Investigational New Drug (IND) application in the fourth quarter of 2026, with a Phase 1 study planned to begin by year-end.
On the financial side, the critical variable is capital. With $116.8 million in cash at the end of June 2026 and guidance into the third quarter of 2027, investors should monitor whether spending trends remain disciplined and whether any financing activity is disclosed. Cost management, data timing, and execution across these three programs will likely shape the stock's trajectory more than the quarterly loss itself. I'm watching this closely as the data readouts approach.
AI-Powered Research in Practice
In my analysis of names like NMRA, I often turn to Tickeron’s AI Screener to quickly filter biotech peers by fundamentals, volatility, and technical signals. It helps surface comparable opportunities without spending hours on manual searches, which is particularly useful when tracking event-driven stories in neuroscience and early-stage development. This approach keeps the focus on data-driven comparisons rather than isolated headlines.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for NMRA turns positive, indicating new upward trend
NMRA saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 50 similar instances where the indicator turned positive. In 44 of the 50 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Oscillator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for NMRA just turned positive on October 08, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in 16 of 20 cases over the following month. The odds of a continued upward trend are 80%.
Following a +55.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NMRA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NMRA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.055) is normal, around the industry mean (2.904). P/E Ratio (-0.396) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. NMRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement